FEXOFENADINE HYDROCHLORIDE HIVES Drug Patent Profile
✉ Email this page to a colleague
When do Fexofenadine Hydrochloride Hives patents expire, and what generic alternatives are available?
Fexofenadine Hydrochloride Hives is a drug marketed by Dr Reddys Labs Ltd, Rising, Sciegen Pharms Inc, Sun Pharm Inds, Teva, and Wockhardt. and is included in six NDAs.
The generic ingredient in FEXOFENADINE HYDROCHLORIDE HIVES is fexofenadine hydrochloride. There are twenty-three drug master file entries for this compound. One hundred and four suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fexofenadine Hydrochloride Hives
A generic version of FEXOFENADINE HYDROCHLORIDE HIVES was approved as fexofenadine hydrochloride by TEVA on September 1st, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FEXOFENADINE HYDROCHLORIDE HIVES?
- What are the global sales for FEXOFENADINE HYDROCHLORIDE HIVES?
- What is Average Wholesale Price for FEXOFENADINE HYDROCHLORIDE HIVES?
Summary for FEXOFENADINE HYDROCHLORIDE HIVES
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 54 |
Raw Ingredient (Bulk) Api Vendors: | 128 |
Clinical Trials: | 79 |
Patent Applications: | 1,698 |
DailyMed Link: | FEXOFENADINE HYDROCHLORIDE HIVES at DailyMed |
Recent Clinical Trials for FEXOFENADINE HYDROCHLORIDE HIVES
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bristol-Myers Squibb | Phase 1 |
Dhaka Medical College | Phase 2/Phase 3 |
Opella Healthcare Group SAS, a Sanofi Company | Phase 3 |
Pharmacology for FEXOFENADINE HYDROCHLORIDE HIVES
Drug Class | Histamine-1 Receptor Antagonist |
Mechanism of Action | Histamine H1 Receptor Antagonists |